1 / 17

The Successful Use of HAART in a Resource Poor Country

The Successful Use of HAART in a Resource Poor Country. Dr.Ellen Koenig, Dr. Carlos Adon, Dr. Maria Amador, Dr. Scarlet Cueto, Dr. Miguel Duran, Lic. Lidia Amador. Instituto Dominicano de Estudios Virologicos. Santo Domingo, Dominican Republic. Distribution of Patients by Sex.

lilly
Download Presentation

The Successful Use of HAART in a Resource Poor Country

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. The Successful Use of HAART in a Resource Poor Country Dr.Ellen Koenig, Dr. Carlos Adon, Dr. Maria Amador, Dr. Scarlet Cueto, Dr. Miguel Duran, Lic. Lidia Amador

  2. Instituto Dominicano de Estudios Virologicos Santo Domingo, Dominican Republic

  3. Distribution of Patients by Sex

  4. Origin ofPatients

  5. Distribution of Patients’ Ages >60 years 18-30 years 46-60 years 31-45 years

  6. Initial Number of CD4/ml

  7. Initial Viral Load (Copies / ml) >100,000 copies 5000-30,0000 copies 55,001-100,000 copies 30,001-55,000 copies

  8. Fate of the 96 Patients who began the Clinical Trial > 3 months < 3months

  9. Reasons for Leaving Study • Withdrew consent 4 persons • God had cured her 1 person • GI problems 5 persons • Allergic reaction 1 person • Lost to follow up 3 persons • Virological Failure Probably Resistant 9 persons Shared with Partner 1 persons Low compliance 4 persons

  10. Weeks until Viral Load Undetectable Number of Patients

  11. Change in CD4 Counts when VL was undetectable

  12. Initial Viral Load (copies/ml) vs. Time to <50 Viral Load

  13. Time to Undetectable Viral Load as a Function of Initial CD4 Count

  14. Initial CD4 vs Change in CD4 when Viral Load Became Undetectable

  15. Change in CD4 vs Initial Viral Load when Viral Load Became Undetectable

  16. SUMMARY • Satisfaction • Education • Surprises

  17. Our thanks also to • Lic. Clara Carvajal • Ms. Clara Aponte • Lic. Ana Maria Castro • Lic. Sandra Encarnación • Ms. Altagracia Sánchez • Mr. Franklin Grullón • Mr. Viriato Matos

More Related